Relevant factors for treatment outcome and time to healing in medication-related osteonecrosis of the jaws - A retrospective cohort study

被引:26
作者
Martins, Ana Silva [1 ]
Correia, Joao Andre [1 ]
Salvado, Francisco [1 ]
Caldas, Cecilia [1 ]
Santos, Nuno [1 ]
Capelo, Antonio [1 ]
Palmela, Paulo [1 ]
机构
[1] Hosp Santa Maria, Ctr Hosp Lisboa Norte, Stomatol & Oral Surg Dept, Lisbon, Portugal
关键词
MRONJ; Osteonecrosis; Bisphosphonates; Denosumab; Sunitinib; BISPHOSPHONATE-RELATED OSTEONECROSIS; BREAST-CANCER PATIENTS; RISK-FACTORS; ZOLEDRONIC ACID; BONE METASTASES; DENOSUMAB; TRIALS;
D O I
10.1016/j.jcms.2017.07.014
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Background: Risk factors for medication-related osteonecrosis of the jaw (MRONJ) are well known, although few studies evaluate the factors that influence treatment outcomes in MRONJ and whether discontinuing antiresorptive medication influences healing. Purpose: (1) Describe the characteristics of a population of patients with MRONJ. (2) Identify the factors associated with favourable outcomes. (3) Identify a temporal correlation between discontinuation of antiresorptives and healing time. Methods: A retrospective longitudinal cohort study was carried out, including 77 patients with MRONJ treated between 2004 and 2016. Primary outcome was defined as healed/improved vs. worse/stable. Time to healing was set as the secondary outcome. Statistical significance was defined as p < 0.05. Results: Primary disease, route of administration, lesion location, and development of complications influenced the outcome of treatment. Significant differences in outcomes according to primary disease (p < 0.05) were found when staging, gender, and lesion location were held constant. Time to healing was longer for patients who discontinued medication more than 3 months after diagnosis than for those who discontinued at diagnosis or before - respectively, 36, 9, and 7 months (p - 0.01). Conclusions: The outcome of MRONJ treatment may be influenced by primary disease and route of administration of antiresorptives. Antiresorptive medication discontinuation contributes to reduce healing time in MRONJ. (C) 2017 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:1736 / 1742
页数:7
相关论文
共 30 条
  • [1] Pathophysiology of Osteonecrosis of the Jaws
    Aghaloo, Tara
    Hazboun, Renna
    Tetradis, Sotirios
    [J]. ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA, 2015, 27 (04) : 489 - +
  • [2] Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy
    De Cock, E
    Hutton, J
    Canney, P
    Body, JJ
    Barrett-Lee, P
    Neary, MP
    Lewis, G
    [J]. SUPPORTIVE CARE IN CANCER, 2005, 13 (12) : 975 - 986
  • [3] The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors
    Dodson, Thomas B.
    [J]. ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA, 2015, 27 (04) : 509 - +
  • [4] Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
    Fizazi, Karim
    Carducci, Michael
    Smith, Matthew
    Damiao, Ronaldo
    Brown, Janet
    Karsh, Lawrence
    Milecki, Piotr
    Shore, Neal
    Rader, Michael
    Wang, Huei
    Jiang, Qi
    Tadros, Sylvia
    Dansey, Roger
    Goessl, Carsten
    [J]. LANCET, 2011, 377 (9768) : 813 - 822
  • [5] Furtado IA, 2012, ACTA MEDICA PORT, V25, P106
  • [6] Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis
    Gaudin, Elise
    Seidel, Laurence
    Bacevic, Miljana
    Rompen, Eric
    Lambert, France
    [J]. JOURNAL OF CLINICAL PERIODONTOLOGY, 2015, 42 (10) : 922 - 932
  • [7] The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid Data from the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly clinical trials program
    Grbic, John T.
    Black, Dennis M.
    Lyles, Kenneth W.
    Reid, David M.
    Orwoll, Eric
    McClung, Michael
    Bucci-Rechtweg, Christina
    Su, Guoqin
    [J]. JOURNAL OF THE AMERICAN DENTAL ASSOCIATION, 2010, 141 (11) : 1365 - 1370
  • [8] Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer
    Guarneri, Valentina
    Miles, David
    Robert, Nicholas
    Dieras, Veronique
    Glaspy, John
    Smith, Ian
    Thomssen, Christoph
    Biganzoli, Laura
    Taran, Tanya
    Conte, PierFranco
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2010, 122 (01) : 181 - 188
  • [9] Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
    Henry, David H.
    Costa, Luis
    Goldwasser, Francois
    Hirsh, Vera
    Hungria, Vania
    Prausova, Jana
    Scagliotti, Giorgio Vittorio
    Sleeboom, Harm
    Spencer, Andrew
    Vadhan-Raj, Saroj
    von Moos, Roger
    Willenbacher, Wolfgang
    Woll, Penella J.
    Wang, Jianming
    Jiang, Qi
    Jun, Susie
    Dansey, Roger
    Yeh, Howard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (09) : 1125 - 1132
  • [10] Temporal Correlation Between Bisphosphonate Termination and Symptom Resolution in Osteonecrosis of the Jaw: A Pooled Case Report Analysis
    Hinson, Andrew M.
    Siegel, Eric R.
    Stack, Brendan C., Jr.
    [J]. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2015, 73 (01) : 53 - 62